Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review

Chaogang Yang; Kun Zou; Liang Zheng; Bin Xiong

doi:10.1186/s12885-017-3704-8

PMC full text:

BMC Cancer. 2017; 17: 725.

Published online 2017 Nov 7. doi: 10.1186/s12885-017-3704-8

Copyright/LicenseRequest permission to reuse

Table 1

Baseline characteristics of the included studies

Article	Country	Number (M/F)^a	Age Mean ± SD^b/Median (range) (y^c)	TS^d	Markers	Adjuvant therapy	ST^e	Rate (+)^f	OM^g	HR^h estimate	CSⁱ	MA^j
Kust 2016 [33]	Croatia	82(49/33)	Mean:66 ± 9.6	I-III	CK20	Post-OP^k CT^l for III and part of II	Pre-OP	22 (26.83%)	OS^m DFSⁿ	Data extrapolated	Yes	No
Liu 2013 [28]	China	92(60/32)	Mean:66 ± 9.6	I-III	CK20	_	Pre-OP	31 (25%)	OS DFS	Reported in text	Yes	Yes
Liu 2013 (1) [28]	China	41(NR)	NR^o	II	CK20	Without	_	NR	OS DFS	Reported in text	Yes	Yes
Liu 2013 (2) [28]	China	51(NR)	NR	III	CK20	Post-OP CT	_	NR	OS DFS	Reported in text	Yes	Yes
Yokobori (1) 2013 [29]	Japan	Training: 151(86/65)	Mean:66.76 ± 11.02	II	PLS3	Without	Pre-OP	33 (21.85%)	OS DFS	Reported in text	Yes	Yes
Yokobori (2) 2013 [29]	Japan	Training: 131(75/56)	Mean:66.76 ± 11.02	III	PLS3	Post-OP CT	Pre-OP	38 (29%)	OS DFS	Reported in text	Yes	Yes
Yokobori (3) 2013 [29]	Japan	Validation: 158(96/62)	Mean:67.51 ± 11.08	II	PLS3	Without	Pre-OP	35 (22.15%)	OS DFS	Reported in text	Yes	Yes
Yokobori (4) 2013 [29]	Japan	Validation: 103(63/40)	Mean:67.51 ± 11.08	III	PLS3	Post-OP CT	Pre-OP	30 (29.12%)	OS DFS	Reported in text	Yes	Yes
Shimada (1) 2012 [19]	Japan	111(60/51)	Median:68(27–82)	II	CEA, CK19, CK20, CD133	Without	Post-OP	63 (56.76%)	OS DFS	Reported in text	Yes	Yes
Shimada (2) 2012 [19]	Japan	86(47/39)	Median:68(27–82)	III	CEA, CK19, CK20, CD133	Post-OP CT	Post-OP	61 (70.93%)	OS DFS	Reported in text	Yes	Yes
Iinuma (1) 2011 [30]	Japan	Training: 420(224/196)	Mean:66.0 ± 12.4	I-III	CEA, CK19, CK20, CD133	_	Post-OP	106(25.24%)	OS DFS	Reported in text	Yes	Yes
Iinuma (1–1) 2011 [30]	Japan	Training: 176(NR)	NR	II	CEA, CK19, CK20, CD133	Without	_	NR	OS DFS	Reported in text	Yes	Yes
Iinuma (1–2) 2011 [30]	Japan	Training:150(NR)	NR	III	CEA, CK19, CK20, CD133	Post-OP CT	_	NR	OS DFS	Reported in text	Yes	Yes
Iinuma (2) 2011 [30]	Japan	Validation: 315(175/140)	Mean:66.0 ± 12.4	I-III	CEA, CK19, CK20, CD133	_	Post-OP	75(23.81%)	OS DFS	Reported in text	Yes	Yes
Iinuma (2–1) 2011 [30]	Japan	Validation: 143(NR)	NR	II	CEA, CK19, CK20, CD133	Without	_	NR	OS DFS	Reported in text	Yes	Yes
Iinuma (2–2) 2011 [30]	Japan	Validation: 97(NR)	NR	III	CEA, CK19, CK20, CD133	Post-OP CT	_	NR	OS DFS	Reported in text	Yes	Yes
Uen 2008 [31]	China	438(234/204)	NR	I-III	CK19, CK20, CEA, hTERT	Post-OP CT for III and part of II	Post-OP (1 W^p)	137 (31.27%)	DFS	Reported in text	Yes	Yes
Barreto 2007 [32]	UK	113(NR)	Mean:67	I-III	CEA, CK20	Post-OP CT for III and part of II	Post-OP (24 h^q)	34 (30.09%)	DFS	Reported in text	Yes	Yes
Koch 2006 [33]	Germany	90(59/31)	Mean:66.1	II	CK20	Post-OP CT for rectal cancer	Post-OP	28 (31.1%)	OS DFS	Reported in text	Yes	No
Lloyd 2006 [34]	Australia	125 (74/51)	Median:74 (43–95)	I-II	CK20, CEA, EphB4, LAMγ2, MAT	Without	Pre-OP	5 (4%)	DFS	Data extrapolated	Yes	No
Sadahrio 2005 [35]	Japan	100(NR)	NR	I-III	CEA	NR	Intra-OP	39 (39%)	OS DFS	Data extrapolated	Yes	Yes
Bessa 2003 [36]	Spain	66 (23/43)	Median:73	I-III	CEA	Post-OP CT for III and part of II	Post-OP	36 (54.55%)	OS DFS	Reported in text	Yes	Yes
Ito 2002 [37]	Japan	99(62/37)	NR	I-III	CEA	NR	Post-OP	26 (26.26%)	DFS	Data extrapolated	Yes	No

Open in a separate window

NOTE: ^a M/F Male/female, ^b SD Standard deviation, ^c Y Year, ^d TS Tumor stage (UICC), ^e ST Sampling time, ^f Rate (+) Rate of CTCs-positive patients, ^g OM Outcome measured, ^h HR Hazard ratio, ⁱ CS Curative surgery, ^j MA Multivariance analysis, ^k OP Operation, ^l CT Chemotherapy, ^m OS Overall survival, ⁿ DFS Disease-free survival, ^o NR Not reported, ^p W Week, ^q h hour